Morepen Laboratories
Ticker > Company >

Morepen Laboratories share price

Morepen Laboratories Ltd.

NSE: MOREPENLAB BSE: 500288 SECTOR: Pharmaceuticals & Drugs  2.44 L   1.57 K   277

46.67
0 0
BSE: 29 Aug 04:01 PM

Price Summary

Today's High

₹ 47.51

Today's Low

₹ 46.46

52 Week High

₹ 100.8

52 Week Low

₹ 41.66

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 2557.3 Cr.

Enterprise Value

₹ 2589.93 Cr.

No. of Shares

54.8 Cr.

P/E

34.29

P/B

2.15

Face Value

₹ 2

Div. Yield

0.43 %

Book Value (TTM)

₹  21.71

CASH

₹ 46.33 Cr.

DEBT

₹ 78.96 Cr.

Promoter Holding

35.65 %

EPS (TTM)

₹  1.36

Sales Growth

1.1%

ROE

9.81 %

ROCE

13.29%

Profit Growth

-8.44 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Morepen Laboratories Ltd.

Forever Young Burnol Lemolate Fibre-X QuickChek Exygra Itch Beat 2 Kool Hair Oil

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year1.1%
3 Year2.36%
5 Year14.44%

Profit Growth

1 Year-8.44%
3 Year0.17%
5 Year25.73%

ROE%

1 Year9.81%
3 Year9.98%
5 Year15.46%

ROCE %

1 Year13.29%
3 Year13.38%
5 Year17.68%

Debt/Equity

0.0668

Price to Cash Flow

87.95

Interest Cover Ratio

20.3703

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 35.65 0.00
Mar 2025 35.65 0.00
Dec 2024 35.65 0.00
Sep 2024 35.65 0.00
Jun 2024 38.22 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 20.3703.
  • The company has an efficient Cash Conversion Cycle of 12.1942 days.
  • Company has a healthy liquidity position with current ratio of 2.3979.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.62692387339684.

 Limitations

  • The company has shown a poor profit growth of 0.16868596778159% for the Past 3 years.
  • The company has shown a poor revenue growth of 2.36480578010212% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 385.64 383.7 403.26 381.94 391.28
Total Expenditure 337.03 340.64 371.68 351.78 372.33
Operating Profit 48.61 43.07 31.58 30.16 18.95
Other Income 3.07 4.63 4.87 3.14 4.09
Interest 1.04 1.05 1.27 3.74 3.81
Depreciation 3.59 3.79 4.81 12.25 7.88
Exceptional Items 0 0 0 0 0
Profit Before Tax 47.05 42.86 30.38 17.3 11.35
Tax 12 10.93 7.69 5.39 3.29
Profit After Tax 35.05 31.93 22.69 11.91 8.06
Adjusted EPS (Rs) 0.69 0.58 0.41 0.22 0.15

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 1112.42 1449.27 1338.88 1537.59 1554.54
Total Expenditure 1000.05 1320.13 1261.61 1375.77 1401.12
Operating Profit 112.37 129.14 77.27 161.82 153.41
Other Income 11.77 20.03 5.76 12.57 15.72
Interest 1.79 2.43 1.98 3.51 7.1
Depreciation 28.11 21.19 18.01 21.9 24.44
Exceptional Items 0 0 0 0 0
Profit Before Tax 94.25 125.54 63.04 148.98 137.59
Tax 0 24.48 16.8 38.04 36.01
Net Profit 94.25 101.06 46.24 110.94 101.58
Adjusted EPS (Rs.) 2.1 2.12 0.9 2.17 1.85

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 89.96 95.56 102.23 102.23 109.58
Total Reserves 355.01 502.61 677.89 786.8 1071.92
Borrowings 0.83 1.32 0.93 3.36 25.76
Other N/C liabilities 26.06 31.09 33.52 34.28 52.39
Current liabilities 375.63 402.69 290.98 352.64 461.56
Total Liabilities 847.5 1033.26 1105.54 1279.31 1721.2
Assets
Net Block 144.02 156.11 170.82 216.54 365.87
Capital WIP 1.96 14.15 17.01 24.45 28.34
Intangible WIP 0 0 0 0 0
Investments 118.78 117.79 117.84 126.18 127.17
Loans & Advances 89.67 68.17 68.74 68.99 92.81
Other N/C Assets 0.27 0.28 0.28 0.24 0.23
Current Assets 492.79 676.76 730.85 842.91 1106.78
Total Assets 847.5 1033.26 1105.54 1279.31 1721.2
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 94.25 125.54 63.04 148.98 137.59
Adjustment 29.63 13.02 18.01 22.7 31.93
Changes in Assets & Liabilities -74.56 -183.04 -166.9 -56.96 -104.37
Tax Paid 0 -24.39 -16.27 -37.36 -36.07
Operating Cash Flow 49.31 -68.87 -102.12 77.36 29.08
Investing Cash Flow -69.09 -22.64 -36.2 -83.6 -280.42
Financing Cash Flow 47.46 66.41 144.2 0.28 260.47
Net Cash Flow 27.68 -25.09 5.88 -5.96 9.12

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 38.22 35.65 35.65 35.65 35.65
aakriti suri 0.01 0.01 0.01 0.01 0.01
aanandi suri 0.15 0.14 0.14 0.14 0.14
aanchal suri 0.13 0.13 0.13 0.13 0.13
anju suri 1.01 0.95 0.95 0.95 0.95
anubhav suri 0.15 0.14 0.14 0.14 0.14
anubhav suri (arunsuri so... 0.29 0.27 0.27 0.27 0.27
brook investments and fin... 2.97 2.77 2.77 2.77 2.77
concept credits and consu... 3.00 2.80 2.80 2.80 2.80
epitome holdings pvt.ltd.... 2.84 2.65 2.65 2.65 2.65
gulfy malhotra 0.22 0.21 0.21 0.21 0.21
kanak suri 0.20 0.18 0.18 0.18 0.18
late p.l. suri - - 0.07 0.07 0.07
liquid holdings pvt. ltd.... 0.98 0.91 0.91 0.91 0.91
mamta suri 0.59 0.55 0.55 0.55 0.55
master arjun suri 0.14 0.13 0.13 0.13 0.13
mid med financial service... 2.93 2.73 2.73 2.73 2.73
rajas suri 0.03 0.03 0.03 0.03 0.03
rajas suri (kb surisons h... 0.19 0.18 0.18 0.18 0.18
react investments and fin... 2.92 2.73 2.73 2.73 2.73
sanjay suri 0.67 0.62 0.62 0.62 0.62
sanjay suri (sanjaysuri s... 0.41 0.38 0.38 0.38 0.38
sara suri 0.14 0.13 0.13 0.13 0.13
scope credits and financi... 3.05 2.84 2.84 2.84 2.84
seed securities and servi... 2.80 2.61 2.61 2.61 2.61
shalu suri 0.40 0.37 0.37 0.37 0.37
solace investments and fi... 2.95 2.75 2.75 2.75 2.75
solitary investments and ... 2.96 2.76 2.76 2.76 2.76
sonia pankaj bajaj 0.72 0.67 0.67 0.67 0.67
square investments and fi... 2.76 2.57 2.57 2.57 2.57
sunita suri 0.62 0.58 0.58 0.58 0.58
sushil suri 1.08 1.00 1.00 1.00 1.00
sushil suri (sushilsuri s... 0.24 0.22 0.22 0.22 0.22
varun suri 0.60 0.56 0.56 0.56 0.56
p.l. suri 0.08 0.07 - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 61.78 64.35 64.35 64.35 64.35
pinfold overseas limited 7.54 7.03 7.03 7.03 7.03
morepen laboratories limi... - 1.02 1.02 1.02 -
morepen laboratories limi... 1.09 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY21
Concall Q3FY24
Concall Q3FY22
Concall Q2FY22
Concall Q1FY25
Concall Q1FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY21
Presentation Q2FY20
Presentation Q1FY22
Presentation Q1FY21

Company News

Morepen Laboratories - Quaterly Results 6 Aug, 2:47 PM Morepen Laboratories - Quaterly Results 6 Aug, 2:47 PM Morepen Laboratories - Quaterly Results 6 Aug, 2:47 PM Morepen Laboratories’ arm to incorporate wholly owned subsidiary 25 Jul, 5:50 PM Morepen Laboratories incorporates step-down subsidiary in Dubai 23 Jul, 11:08 AM Morepen Laboratories incorporates wholly owned subsidiary in Dubai 19 Jun, 10:52 AM Morepen Laboratories informs about outcome of committee meeting 23 May, 12:25 PM Morepen Laboratories informs about newspaper publication 13 May, 5:31 PM Morepen Laboratories reports 29% fall in Q4 consolidated net profit 13 May, 12:29 PM Morepen Laboratories informs about press release 13 May, 12:21 PM Morepen Laboratories informs about audited financial results 12 May, 6:01 PM Morepen Laboratories - Quaterly Results 12 May, 3:54 PM Morepen Laboratories - Quaterly Results 12 May, 3:54 PM Morepen Laboratories - Quaterly Results 12 May, 3:54 PM Morepen Laboratories to launch new drug for Fatty Liver 29 Apr, 12:50 PM Morepen Laboratories gets nod to incorporate wholly owned subsidiary in Dubai 29 Apr, 10:09 AM Morepen Laboratories informs about press release 29 Apr, 9:40 AM Morepen Laboratories informs about launch of new products 24 Apr, 2:25 PM Morepen Laboratories informs about press release 11 Apr, 11:41 AM Morepen Laboratories informs about press release 1 Apr, 11:40 AM Morepen Laboratories secures Loratadine approval for export to China 1 Apr, 9:50 AM Morepen Laboratories incorporates step-down subsidiary 20 Mar, 6:02 PM Morepen Laboratories to transfer Medical Devices Business 19 Mar, 2:46 PM Morepen Laboratories launches Empamore 18 Mar, 9:29 AM Morepen Laboratories’ arm gets nod to form new subsidiary company 19 Feb, 2:51 PM Morepen Laboratories - Quaterly Results 6 Feb, 2:11 PM Morepen Laboratories - Quaterly Results 6 Feb, 2:11 PM Morepen Laboratories - Quaterly Results 6 Feb, 2:11 PM Morepen Laboratories informs about newspaper publication 18 Jan, 5:04 PM Morepen Laboratories to hive off medical devices business 15 Jan, 11:30 AM Morepen Laboratories incorporates subsidiary company 9 Jan, 9:44 AM Morepen Laboratories’ arm introduces weight management program ‘LightLife’ 11 Dec, 12:58 PM Morepen Laboratories - Quaterly Results 11 Nov, 2:28 PM Morepen Laboratories - Quaterly Results 11 Nov, 2:28 PM Morepen Laboratories - Quaterly Results 11 Nov, 2:28 PM Morepen Laboratories informs about loss of share certificates 23 Oct, 3:34 PM Morepen Laboratories informs about clarification on price movement 26 Aug, 12:40 PM Morepen Laboratories informs about earnings call transcript 17 Aug, 3:37 PM Morepen Laboratories informs about press release 12 Aug, 3:30 PM Morepen Laboratories - Quaterly Results 12 Aug, 10:04 AM Morepen Laboratories - Quaterly Results 12 Aug, 10:04 AM Morepen Laboratories - Quaterly Results 12 Aug, 10:04 AM Morepen Laboratories informs about press release 6 Aug, 9:56 AM Morepen Laboratories informs about loss of share certificates 22 Jun, 12:51 PM Morepen Laboratories - Quaterly Results 21 May, 7:05 PM Morepen Laboratories - Quaterly Results 21 May, 7:05 PM Morepen Laboratories informs about PCS certificate 23 Apr, 5:55 PM Morepen Laboratories informs about outcome of EGM 18 Mar, 4:13 PM Morepen Laboratories informs about outcome of board meeting 31 Jan, 3:59 PM Morepen Laboratories - Quaterly Results 31 Jan, 2:22 PM

Morepen Laboratories Stock Price Analysis and Quick Research Report. Is Morepen Laboratories an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Morepen Laboratories. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Morepen Laboratories has a PE ratio of 34.256538348516 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Morepen Laboratories has ROA of 6.7705% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Morepen Laboratories has a Current ratio of 2.3979.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Morepen Laboratories has a ROE of 9.8115%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Morepen Laboratories has a Debt to Equity ratio of 0.0668 which means that the company has low proportion of debt in its capital.

  • Sales growth: Morepen Laboratories has reported revenue growth of 1.1018% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Morepen Laboratories for the current financial year is 9.8686083230146%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Morepen Laboratories is Rs 0.2 and the yield is 0.4285%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Morepen Laboratories is Rs 1.3612. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Morepen Laboratories in Ticker for free. Also, one can get the intrinsic value of Morepen Laboratories by using Valuation Calculators, which are available with a Finology ONE subscription. 

Morepen Laboratories FAQs

Q1. What is Morepen Laboratories share price today?
Ans: The current share price of Morepen Laboratories is Rs 46.63.

Q2. What is the market capitalisation of Morepen Laboratories?
Ans: Morepen Laboratories has a market capitalisation of Rs 2555.108098437 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Morepen Laboratories?
Ans: The PE ratio of Morepen Laboratories is 34.256538348516 and the P/B ratio of Morepen Laboratories is 2.14792738595901, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Morepen Laboratories share?
Ans: The 52-week high share price of Morepen Laboratories is Rs 100.9, and the 52-week low share price of Morepen Laboratories is Rs 42.

Q5. Does Morepen Laboratories pay dividends?
Ans: Currently, Morepen Laboratories pays dividends. Dividend yield of Morepen Laboratories is around 0.4285%.

Q6. What are the face value and book value of Morepen Laboratories shares?
Ans: The face value of Morepen Laboratories shares is Rs 2, while the book value per share of Morepen Laboratories is around Rs 21.7093. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Morepen Laboratories?
Ans: Morepen Laboratories has a total debt of Rs 78.9596 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Morepen Laboratories?
Ans: The ROE of Morepen Laboratories is 9.8115% and ROCE of Morepen Laboratories is 13.2883%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Morepen Laboratories a good buy for the long term?
Ans: The Morepen Laboratories long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Morepen Laboratories undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Morepen Laboratories appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Morepen Laboratories’s financials?
Ans: You can review Morepen Laboratories’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Morepen Laboratories

Morepen Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Morepen Laboratories Ltd. is a leading pharmaceutical company in India that specializes in the manufacturing and supply of bulk drugs, formulations, diagnostics, and APIs. With a rich history of more than three decades, Morepen has established itself as a trusted name in the healthcare industry. The company is known for its commitment to quality, innovation, and customer satisfaction.

Morepen Laboratories Ltd. - Share Price

Stay updated with the latest share price of Morepen Laboratories Ltd. Our website provides real-time information on the stock's performance in the market. By tracking the share price, investors can make informed decisions regarding buying, selling, or holding their positions in Morepen Laboratories Ltd.

Morepen Laboratories Ltd. - Balance Sheet

Access the balance sheet of Morepen Laboratories Ltd. to get a comprehensive understanding of the company's financial position. Our pre-built screening tools enable investors to analyze the balance sheet and identify key financial indicators without the need for complex calculations. We provide downloadable annual reports that serve as a valuable resource for conducting a thorough analysis.

Morepen Laboratories Ltd. - Annual Report

The annual report of Morepen Laboratories Ltd. contains a wealth of information that can assist investors in evaluating the company's performance over the past year. Our website offers downloadable annual reports, enabling investors to gain insights into the company's financials, business strategies, and future prospects.

Morepen Laboratories Ltd. - Dividend

Discover the dividend history of Morepen Laboratories Ltd. by exploring our website. Investors interested in dividend income can track the company's dividend payouts over the years. Our platform provides a user-friendly interface where investors can access the latest dividend announcements and historical dividend data.

Morepen Laboratories Ltd. - Quarterly Result

Stay updated with the quarterly results of Morepen Laboratories Ltd. Our website provides access to the company's financial performance for each quarter. Investors can analyze the quarterly reports, along with our premium features such as fair value calculation using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Morepen Laboratories Ltd. - Stock Price

Track the stock price of Morepen Laboratories Ltd. and monitor its movement in the market on a daily basis. Our website provides a comprehensive chart that displays the historical price data, allowing investors to identify trends and patterns. By understanding the stock price dynamics, investors can make informed decisions about their investment in Morepen Laboratories Ltd.

Morepen Laboratories Ltd. - Price Chart

Our website offers an interactive price chart that allows investors to visualize the historical price movement of Morepen Laboratories Ltd. This tool enables users to analyze the stock's performance over different time frames and identify trends, support, and resistance levels. The price chart serves as a valuable resource for technical analysis.

Morepen Laboratories Ltd. - News

Stay updated with the latest news and developments related to Morepen Laboratories Ltd. Our website provides a dedicated news section where investors can access relevant news articles, press releases, and market updates. By staying informed, investors can make well-informed decisions based on the latest information.

Morepen Laboratories Ltd. - Concall Transcripts

Access the concall transcripts of Morepen Laboratories Ltd. to gain insights into the company's quarterly earnings calls and management discussions. Our platform offers downloadable concall transcripts, enabling investors to study the key highlights, decisions, and future plans discussed during these calls.

Morepen Laboratories Ltd. - Investor Presentations

Morepen Laboratories Ltd. regularly publishes investor presentations that provide an overview of the company's operations, financial performance, and growth prospects. Our platform offers downloadable investor presentations, allowing investors to delve into the details and understand the dynamics of Morepen Laboratories Ltd.

Morepen Laboratories Ltd. - Promoters

Learn about the promoters of Morepen Laboratories Ltd. and their contribution to the company's growth and success. Our website provides detailed information about the promoters, their background, and the roles they play in the company's management and decision-making processes.

Morepen Laboratories Ltd. - Shareholders

Discover the major shareholders of Morepen Laboratories Ltd. and their influence on the company's governance and strategic decisions. Our platform offers insights into the shareholding pattern of the company, providing investors with a holistic view of the ownership structure.

With our website’s comprehensive resources and pre-built screening tools, investors can conduct a thorough stock analysis of Morepen Laboratories Ltd. Make use of our downloadable annual reports, concall transcripts, investor presentations, and other valuable features to gain a deeper understanding of the company's financial health, market performance, and growth potential. 

Morepen Laboratories Balance Sheet Analysis

Morepen Laboratories Reserves Growth

Analyzing the data of Morepen Laboratories, the total reserves of the company have shown a notable upward trajectory from March 2020 to March 2024. Starting at Rs 217.29 Cr in March 2020, the reserves escalated to Rs 786.80 Cr by March 2024, reflecting solid financial reinforcement and retained earnings growth.

Morepen Laboratories Debt Overview

A glance at the borrowings reveals a minimal and well-managed debt profile for Morepen Laboratories. The borrowings fluctuated slightly over the years but remained low, peaking at Rs 3.36 Cr by March 2024, suggesting a conservative approach to leveraging and financial stability.

Morepen Laboratories Assets Expansion

The assets of Morepen Laboratories have witnessed a substantial increase indicating robust growth. The net block, which constitutes the tangible assets, expanded from Rs 134.84 Cr in March 2020 to Rs 216.54 Cr by March 2024. Concurrently, current assets rose significantly from Rs 348.26 Cr to Rs 842.91 Cr, underlining strong operational efficiency and liquidity.

This analysis derives from the Standalone Balance Sheet of Morepen Laboratories, reflecting its financial health and growth over the specified period.

Additionally, investors tracking the pharmaceutical sector on NSE/BSE indices may find Morepen Laboratories a potential candidate for their investment portfolio, given its solid balance sheet performance.

Read More
X